FR3061716B1 - Nouveaux composes ciblant le cd160 humain - Google Patents

Nouveaux composes ciblant le cd160 humain Download PDF

Info

Publication number
FR3061716B1
FR3061716B1 FR1750152A FR1750152A FR3061716B1 FR 3061716 B1 FR3061716 B1 FR 3061716B1 FR 1750152 A FR1750152 A FR 1750152A FR 1750152 A FR1750152 A FR 1750152A FR 3061716 B1 FR3061716 B1 FR 3061716B1
Authority
FR
France
Prior art keywords
seq
human
novel compounds
compounds targeting
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1750152A
Other languages
English (en)
Other versions
FR3061716A1 (fr
Inventor
Alexandre Calcei
Helene HAEGEL
Thierry Menguy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elsalys Biotech
Original Assignee
Elsalys Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1750152A priority Critical patent/FR3061716B1/fr
Application filed by Elsalys Biotech filed Critical Elsalys Biotech
Priority to PCT/EP2018/050354 priority patent/WO2018127586A1/fr
Priority to EP18702410.4A priority patent/EP3565593A1/fr
Priority to US16/476,171 priority patent/US10975159B2/en
Priority to JP2019536858A priority patent/JP7189878B2/ja
Priority to CN201880016030.8A priority patent/CN110381999B/zh
Priority to CA3048799A priority patent/CA3048799A1/fr
Publication of FR3061716A1 publication Critical patent/FR3061716A1/fr
Application granted granted Critical
Publication of FR3061716B1 publication Critical patent/FR3061716B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)

Abstract

La présente invention a pour objet de nouveaux composés qui se lient spécifiquement au CD160 humain, comprenant un domaine variable de chaîne légère (VL) une séquence choisie définie par SEQ ID No:14 ou SEQ ID No:13 et un domaine variable de chaîne lourde (VH) une séquence choisie parmi SEQ ID No:11, SEQ ID No:25, SEQ ID No: 26, SEQ ID No:27, SEQ ID No: 28, SEQ ID No:29 ou SEQ ID No:30 leurs fragments ou leurs dérivés.
FR1750152A 2017-01-06 2017-01-06 Nouveaux composes ciblant le cd160 humain Active FR3061716B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1750152A FR3061716B1 (fr) 2017-01-06 2017-01-06 Nouveaux composes ciblant le cd160 humain
EP18702410.4A EP3565593A1 (fr) 2017-01-06 2018-01-08 Composés se liant au cd160 humain et leurs utilisations
US16/476,171 US10975159B2 (en) 2017-01-06 2018-01-08 Compounds binding human CD160 and uses thereof
JP2019536858A JP7189878B2 (ja) 2017-01-06 2018-01-08 ヒトｃｄ１６０を結合する結合物及びその使用
PCT/EP2018/050354 WO2018127586A1 (fr) 2017-01-06 2018-01-08 Composés se liant au cd160 humain et leurs utilisations
CN201880016030.8A CN110381999B (zh) 2017-01-06 2018-01-08 结合人cd160的化合物及其用途
CA3048799A CA3048799A1 (fr) 2017-01-06 2018-01-08 Composes se liant au cd160 humain et leurs utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1750152A FR3061716B1 (fr) 2017-01-06 2017-01-06 Nouveaux composes ciblant le cd160 humain
FR1750152 2017-01-06

Publications (2)

Publication Number Publication Date
FR3061716A1 FR3061716A1 (fr) 2018-07-13
FR3061716B1 true FR3061716B1 (fr) 2019-05-17

Family

ID=59325344

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1750152A Active FR3061716B1 (fr) 2017-01-06 2017-01-06 Nouveaux composes ciblant le cd160 humain

Country Status (7)

Country Link
US (1) US10975159B2 (fr)
EP (1) EP3565593A1 (fr)
JP (1) JP7189878B2 (fr)
CN (1) CN110381999B (fr)
CA (1) CA3048799A1 (fr)
FR (1) FR3061716B1 (fr)
WO (1) WO2018127586A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613664A (zh) * 2019-03-01 2021-11-05 阿奇洛伊斯生物制药公司 在抗原特异性免疫细胞中调节cd160功能的方法及其用途
GB202103706D0 (en) * 2021-03-17 2021-04-28 Ucl Business Ltd CD160 binding domain

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5253898A (en) 1996-11-12 1998-06-03 Dana-Farber Cancer Institute Recombinant by55 and nucleic acids encoding same
KR101086533B1 (ko) * 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US20050042664A1 (en) * 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
EP1626059A1 (fr) * 2004-08-09 2006-02-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Applications angiogéniques et immunologiques de composés spécifiques anti-CD160 pouvant être obtenus à partir de l'anticorps monoclonal CL1-R2
MX2007002883A (es) * 2004-09-13 2007-06-15 Macrogenics Inc Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
ES2387312T3 (es) * 2004-09-22 2012-09-20 Kyowa Hakko Kirin Co., Ltd. Anticuerpos IgG4 humanos estabilizados
EP2006299A1 (fr) 2007-06-18 2008-12-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Identification de nouveaux isoformes du récepteur CD160 spécifique de classe I MHC et utilisations associées
EP2210903A1 (fr) * 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anticorps monoclonaux anti-CD 160 et leurs utilisations
CA2796312C (fr) * 2010-05-28 2020-11-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anticorps specifiques anti-cd160 pour un traitement de troubles oculaires basees sur la neoangiogenese
EP2455403A1 (fr) * 2010-11-23 2012-05-23 Pierre Fabre Medicament Anticorps humanisés homogènes contre JAM-A qui inhibitent la prolifération
WO2012096994A2 (fr) * 2011-01-10 2012-07-19 Emory University Anticorps dirigés contre le virus de la grippe
AU2012326025B2 (en) * 2011-10-18 2017-08-31 Emory University Antibodies directed against influenza
US9534054B2 (en) * 2013-05-02 2017-01-03 Ares Trading S.A. Monoclonal antibody directed against CXCR5
RU2718692C2 (ru) * 2014-05-29 2020-04-13 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
CA2977142A1 (fr) * 2015-02-19 2016-08-25 Darrell JOHNSTONE Anticorps humanises anti-filovirus et leurs utilisations
TW201710286A (zh) * 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN108779175B (zh) * 2015-12-28 2022-07-08 依奈特制药公司 NKp46结合蛋白的可变区

Also Published As

Publication number Publication date
FR3061716A1 (fr) 2018-07-13
CA3048799A1 (fr) 2018-07-12
CN110381999A (zh) 2019-10-25
JP2020505013A (ja) 2020-02-20
CN110381999B (zh) 2023-12-01
US10975159B2 (en) 2021-04-13
JP7189878B2 (ja) 2022-12-14
WO2018127586A1 (fr) 2018-07-12
US20200109211A1 (en) 2020-04-09
EP3565593A1 (fr) 2019-11-13

Similar Documents

Publication Publication Date Title
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
CY1120665T1 (el) Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους
NZ743713A (en) Human immunodeficiency virus neutralizing antibodies
CY1123884T1 (el) Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων
CU20190099A7 (es) Dominio de unión a antígeno anti-trbc1, y receptor de antígeno quimérico, anticuerpo, acoplador biespecífico de células t y conjugado anticuerpo-fármaco que comprenden el mismo
MX2022000112A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
MX2017013080A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
CY1124630T1 (el) Επιλεκτικη αναγωγη αντισωματων τροποποιημενης κυστεϊνης
JP2018504907A5 (fr)
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
PH12021550244A1 (en) Anti-btla antibody
EA201991353A1 (ru) Двухвалентные антитела, маскированные спирализованными спиралями
EA202191763A1 (ru) Бифункциональная молекула анти-pd-1/sirp
EA201992756A3 (ru) Антитела против cd48 и их конъюгаты
EP4282434A3 (fr) Anticorps, leurs utilisations et leurs conjugués
PE20230381A1 (es) Proteina de union a rgma
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MX2022002239A (es) Glicovariantes de igm.
CY1121950T1 (el) Νεα αντισωματα εναντι φωσφορυλχολινης
CR20220650A (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso
MX2020007880A (es) Anticuerpos de mica/b y metodos de uso.
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180713

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7